DeepMed Research

Hemay-007

Generic Name: Hemay-007

Clinical Trials

Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis

Phase 2

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: Hemay007

First Posted Date: 2019-06-06

Last Posted Date: 2024-03-01

Lead Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd

Target Recruit Count: 70

Registration Number: NCT03977480

Locations: 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳
Zhengzhou People's Hospital, Zhengzhou, Henan, China

and more 22 locations

PhaseⅠFirst-in-Human Study of Hemay007 in Healthy Volunteers

Phase 1

Conditions: Inflammatory Bowel Disease

Interventions: Drug: Hemay007
Drug: placebo

First Posted Date: 2015-11-11

Last Posted Date: 2017-10-24

Lead Sponsor: Hemay Pharmaceutical PTY. LTD.

Target Recruit Count: 82

Registration Number: NCT02603185

Locations: 🇦🇺
CMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy